Learn how Shinogi Pharma Co., Ltd prepared a system offering total CDMO support for nitrosamine analysis after reacting to the stringent detection limits at or below 0.3 ppm and acceptable limit for nitrosamines in sartan API's.
Key Learning Points:
Discover the full potential of your lab’s nitrosamine analysis—Download the case study to learn more about how you can stay ahead in compliance and accuracy.